Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hexachlorophene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.95 |
| ▸ | HPGD | P15428 | 7/20 | 0.95 |
| ▸ | TSHR | P16473 | 7/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.95 |
| ▸ | RECQL | P46063 | 2/20 | 0.95 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.95 |
| ▸ | THRB | P10828 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.95 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | NPC1 | O15118 | 1/20 | 0.95 |
| ▸ | USP2 | O75604 | 1/20 | 0.95 |
| ▸ | EGFR | P00533 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | ESR1 | P03372 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexachlorophene SCHEMBL15579 | 0.98 | HSD17B10 (1.00) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL29352805 | 0.98 | HSD17B10 (1.00) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL2810158 | 0.95 | HSD17B10 (0.95) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL16339207 | 0.95 | HSD17B10 (0.95) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL2806744 | 0.95 | HSD17B10 (0.95) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL19689282 | 0.95 | HSD17B10 (0.95) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL11693520 | 0.95 | HSD17B10 (0.95) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| Hexachlorophene SCHEMBL28107499 | 0.88 | HPGD (0.74) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| SCHEMBL13287028 | 0.86 | SIRT1 (0.86) | HSD17B10HPGDTSHRCYP3A4HIF1A | |
| SCHEMBL14644982 | 0.86 | SIRT1 (1.00) | HSD17B10HPGDTSHRCYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| US-7563899-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070265293-A1 | Opioid antagonists; lyophilization | PROGENICS PHARMACEUTICAIS, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | HSD17B10 3396/4885HPGD 911/4885TSHR 2866/4885 |
| US-20070265293-A1 | Opioid antagonists; lyophilization | OPRM1, OGFR, OPRL1 | HSD17B10 3872/4885HPGD 2636/4885TSHR 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.